INVENTORY OF SUPPLEMENTAL INFORMATION

Supplemental Data
For each cell type we show, top left: distribution of the reference compound (cycloheximide) EC50 for each plate in the primary screen. The reference compound behaves similarly across all four assays (EC50 ~ 1-10 nM) and is highly reproducible from plate to plate. Top right: Distribution of Z' values for each plate in the bioactive primary screen. All Z' values were above 0.5 with the exception of the last plate in NSC wt . Bottom left: Heatmap of activity z-scores calculated from the average activity of each well across the assay. Column one contained cyclohexmide at a single concentration; columns two and 13 was cycloheximide alternating with DMSO (positive and negative control). Column 14 was a dose response reference curve for cycloheximide. Column one was not included as part of the positive controls due to the apparent edge effect. Bottom right: Dose-response screen summary indicating the potency and frequency of active agents in the secondary screen.
(C to F) Non-ependymoma mouse brain tumor mBT NICD1 . Transplantation of NSC null transduced with the intracellular domain of human NOTCH1 (NICD1) resulted in highly invasive and proliferative brain tumors.
Detailed morphologic, immunohistochemical (by D.W.E.) analysis of these tumors demonstrated these to be malignant expansions of undifferentiated cells devoid of any known neural or glial markers and molecularly distinct from ependymoma. Sections of mBT NICD1 tumors in the brains of mice stained for (C) hematoxylin and eosin (D) Ki67 (demonstrating high rates of proliferation in the tumor) (E) nuclear NICD1 staining in tumor cells (F) lack of glial fibrillary acidic protein staining in tumor. Scale bar 100M Table S1, 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
High-throughput cell viability assay selection and optimization.
For high-throughput drug screening (HTS), cells were cultured as described in 'Experimental Procedures' in 384-well microplates. To determine optimal cell number, cells were seeded at a variety of densities and assayed daily for cell proliferation. Growth curves for each cell type were constructed and used to select a seeding density for use in the HTS which ensured the cells were in an exponential phase of growth for the duration of the assay (96 hours drug exposure). Cell number per well was optimized to 2,000 cells for mEP Cell titre glo was selected due to its high Z' value and its ease of use in HTS since no prolonged incubation step was required between reagent addition and assay readout (Luminescence was read after 15 min on an Envision plate reader, Perkin Elmer). Cells were seeded in a 30µl volume and cell titre glo reagent volume was optimized to 50µl per well (data not shown). A number of inter-day and interplate tests were performed and revealed a stable and robust assay. Intra-plate analysis revealed little drift and minimal edge effects. All signal CVs were less than 20%, all SW's >2 and all Z' factors greater than 0.5. All within-day and between-day fold shifts were less than 2 (data not shown).
A summary of the experimental workflow is reported in Figure S1A . As detailed above, cells were plated in 384-well white plates and at 24 hours, approximately 25nL of compound solutions were pin transferred into the 384-well cell containing assay plates. Plates were placed back in the incubator for 96 hours before being equilibrated at room temperature for 20 min prior to addition of 50 μl Cell Titer Glo to each well. Luminescence was read after approximately 15 min, on an automated Envision plate reader (Perkin-Elmer) after applying a white seal to the bottom of the assay plate. A chemical library of 7,523 compounds was screened in the cell viability assays of mEP Screening quality was assessed by multiple methods including ROC analysis, Z'-prime, Z factor and other screening quality metrics (see Figure 1 in manuscript and Figure S1 ). The discriminatory power of the screen was assessed using receiver operating characteristic (ROC) analysis. Two hundred and fifty-four compounds were selected to sample the primary assay according to the distribution of observed activities. True positives were defined as any compound yielding a well-behaved, saturating sigmoidal curve in the dose-response assay. ROC analysis revealed that the assay has excellent discriminatory power, with AUCs around 0.9 (a perfect assay would have an AUC 1.0, whereas as a random assay has an AUC of 0.5). A cutoff of >50% would afford >80% of all true positives. Tissue samples and genomics. Genomic analysis of mouse tumors and cells was performed exactly as described previously (Johnson et al., 2010) . Real-time PCR was used as previously described (Taylor et al, 2005) to validate the expression levels in mEP 
Kinome
Pharmacokinetics
The initial plasma pharmacokinetic studies were designed to develop a pharmacokinetic limited sampling model (LSM) for unbound 5-fluorouracil, which could be used for each microdialysis study minimizing blood withdrawal and maximizing information content. For these 5-fluorouracil plasma pharmacokinetic studies, two groups of CD-1 nude mice age > 8 weeks weighing 23 to 28 g were Blood samples (50 µL) were collected from each mouse using the limited sampling strategy determined from the studies described above, and four to five 30 min dialysate fractions were collected. After 3 hours (when 5-fluorouracil concentrations were undetectable in plasma and tumor), the probe was calibrated by perfusing a 10 µM 5-fluorouracil solution. After the retrodialysis calibration step, an osmotic pump (Alzet, model 2001D, Cupertino, CA) loaded with 5-fluorouracil (50 mg/mL) delivering 13 mg/kg/h was implanted subcutaneously. Three dialysate fractions of 4 hours each were collected overnight. The next morning (12-16 hours after the insertion of the osmotic pump), a single blood sample was withdrawn (50 µL), the mouse was sacrificed, and the brain
